CLL

October 16, 2018

Publication of Phase 3 Trial Results Supports FDA Approval of Copiktra, Verastem Announces

News

Copiktra (duvelisib) monotherapy may be an effective and safe treatment option for patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to results from a Phase 3 ... Read more

September 18, 2018

Verastem Launches Phase 1/2 Trial to Evaluate Duvelisib-Venclexta Combo in CLL/SLL Patients

News

Verastem Oncology has dosed the first patient in its Phase 1/2 trial testing a combination of duvelisib and Venclexta (venetoclax) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who failed ... Read more

January 2, 2018

Verastem to Seek FDA Approval for Duvelisib to Treat SLL and CLL After Consistently Positive Trial Results

News

Verastem‘s duvelisib significantly delays disease progression or death in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to Phase 3 trial results. The trial, called ... Read more

December 1, 2017December 1, 2017

Eureka Technologies Receives FDA’s OK to Move T-cell Therapy into Clinical Trials

News

The U.S. Food and Drug Administration (FDA) has approved the T-cell therapy ET190L1-ARTEMIS to move into clinical trials for the treatment of relapsed and refractory CD19-positive non-Hodgkin’s lymphoma (NHL). Following the ... Read more

January 13, 2017

$42M European Initiative Aims to Improve Care for Blood Disorder Patients

News

A new European initiative aims to use big data to improve outcomes for patients with blood diseases. Consisting of 51 partners from 11 European countries, the HARMONY project is focused ... Read more

December 5, 2016December 5, 2016

New Lymphoma Hub Online Resource Launch Announced At 2016 American Society of Hematology Annual Meeting

News

The launch of a new subtype-driven online resource for professionals treating and researching lymphoma and chronic lymphocytic leukemia (CLL) blood cancers, was announced at the 2016 American Society of Hematology ... Read more

June 8, 2016June 8, 2016

ASCO 2016 – AbbVie’s Imbruvica Phase 3 Trials in Leukemia and Lymphoma Patients Show Long-Term Favorable Responses

News

AbbVie has just presented long-term data on Imbruvica (ibrutinib) effects in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), revealing its therapeutic potential in these diseases. The ... Read more

May 13, 2016May 13, 2016

FDA Expands Label for Imbruvica (ibrutinib), a Lymphoma Therapy, to Include Improved Survival and Safety

News

The U.S. Food and Drug Administration (FDA) recently approved an expansion to prescribing information for the kinase inhibitor Imbruvica (ibrutinib), based on improved survival, safety, and efficacy data from studies in people with chronic ... Read more

May 2, 2016May 2, 2016

New PI3K Delta Inhibitor to Treat Blood Cancers Shows Promise in Early Clinical Study

News

MEI Pharma recently presented promising clinical results from a new oral phosphatidylinositol 3 kinase (PI3K) delta inhibitor, ME-401, that may improve the therapeutic window in cancer patients compared to other PI3K ... Read more

April 29, 2016April 29, 2016

IBC Generium Chooses Partner to Develop IgG-based Antibody as Possible Lymphoma Treatment

News

IBC Generium (also known as International Biotechnology Center Generium) has selected Goodwin Biotechnology to access, process and manufacture its immunoglobulin G (IgG)-based, bispecific antibody, GNR-047, to prepare it for testing in early clinical trials it plans to conduct in ... Read more